Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER vs ISOLYTE E IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Plasma-Lyte 148 is an isotonic crystalloid solution that provides electrolyte replacement and volume expansion. It mimics plasma electrolyte composition, with acetate and gluconate as bicarbonate precursors that are metabolized to bicarbonate in the liver and kidneys, helping to maintain acid-base balance.
ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.
Intravenous replacement of extracellular fluid losses,Maintenance of fluid and electrolyte balance,Correction of metabolic acidosis,Off-label: Resuscitation in hypovolemia, perioperative fluid management
Maintenance of fluid and electrolyte balance in patients unable to take oral intake,Correction of metabolic acidosis when bicarbonate is contraindicated or not available,Replacement of electrolytes in hypokalemia, hyponatremia, hypomagnesemia, and hypocalcemia
Intravenous infusion; dose determined by electrolyte and fluid requirements. Typical adult rate: 25-100 m L/hour.
Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.
Not applicable; Plasma-Lyte 148 contains electrolytes and water that distribute according to body fluid compartments; infusion rate and renal function dictate elimination; clinical context: in normal renal function, excess fluids and electrolytes are cleared with a half-life of approximately 2-4 hours.
Not applicable as a single agent; components have variable half-lives (e.g., sodium and chloride distribute rapidly with an elimination half-life of 2-4 hours depending on renal function). In renal impairment, half-life may be prolonged.
Acetate and gluconate are metabolized in the liver and kidneys to bicarbonate. Water and electrolytes are not metabolized but undergo renal excretion.
Acetate and gluconate are metabolized in the liver via the tricarboxylic acid cycle to bicarbonate; electrolytes are distributed in body fluids and excreted renally.
Renal: >90% of infused electrolytes and water are excreted unchanged in urine. Biliary/fecal excretion is negligible (<1%).
Renal: >95% of administered electrolytes and water are excreted unchanged by the kidneys, primarily as urine. Biliary/fecal: <5% eliminated via feces, mainly unabsorbed components.
Not applicable; individual electrolytes do not bind to plasma proteins (e.g., sodium, chloride, potassium, magnesium, acetate, gluconate have negligible protein binding).
Minimal to none: electrolytes like sodium, potassium, chloride, and bicarbonate are not protein-bound (<1%). Magnesium and calcium may have 30-50% binding to albumin, but overall negligible in solution.
Not applicable as a single value; electrolytes distribute into total body water (approximately 0.6 L/kg in adults); clinical meaning: initial distribution reflects extracellular fluid expansion.
Distributes primarily into extracellular fluid (ECF) with Vd approximately 0.2 L/kg for sodium and chloride; calcium and magnesium distribute into a larger volume (0.5-0.6 L/kg) due to intracellular uptake.
Intravenous: 100% (directly into systemic circulation).
Intravenous: 100% (complete systemic availability). Not administered orally or by other routes for systemic effect.
No specific dose adjustment; use with caution in renal impairment due to risk of electrolyte imbalances. Monitor serum electrolytes and renal function.
Contraindicated in patients with severe renal impairment (GFR < 30 m L/min) due to risk of hyperkalemia. For GFR 30-50 m L/min, reduce infusion rate by 50% and monitor serum potassium closely. No adjustment needed for GFR > 50 m L/min.
No specific adjustment; use with caution in severe hepatic impairment due to potential for fluid and electrolyte disturbances.
Child-Pugh Class A: no adjustment. Class B: reduce infusion rate by 25% and monitor serum potassium. Class C: use with caution; consider alternative solutions due to risk of electrolyte imbalance.
Intravenous infusion; dose based on weight and clinical status. Typical rate: 5-20 m L/kg/hour, adjust based on response.
Weight-based dosing: 20-30 m L/kg as a single intravenous infusion, administered at a rate not exceeding 5 m L/kg/hour. Maximum total volume: 1000 m L. Adjust based on clinical status and serum electrolytes.
Use with caution due to potential for fluid overload and electrolyte disturbances; monitor renal function and adjust infusion rate accordingly.
Elderly patients may require reduced infusion rates (2-5 m L/min) due to decreased renal function and higher risk of fluid overload. Monitor serum potassium and renal function closely.
None
None
Risk of fluid overload, especially in patients with heart failure or renal impairment,Electrolyte disturbances (hypernatremia, hyperkalemia, hypokalemia, hypercalcemia, hypermagnesemia) may occur,Monitor serum electrolytes, fluid balance, and renal function,Not recommended for use in patients with severe renal impairment or anuria,Use with caution in patients with metabolic alkalosis or conditions with predisposing factors for electrolyte imbalances
Monitor serum electrolytes, fluid balance, and renal function regularly. Use with caution in patients with heart failure, renal impairment, or conditions predisposing to hypervolemia. Avoid rapid infusion; extravasation may cause tissue damage. Contains aluminum, which may accumulate in renal impairment.
Hypersensitivity to any component,Severe renal impairment with oliguria or anuria,Hyperkalemia,Metabolic alkalosis,Clinically significant hypercalcemia,Patients with conditions where sodium retention is a concern (e.g., congestive heart failure, edema, cirrhosis)
Hyperkalemia, hypernatremia, hypercalcemia, hypermagnesemia, severe metabolic alkalosis, severe renal failure with oliguria or anuria, and patients with a known hypersensitivity to any component.
None; PLASMA-LYTE 148 is administered intravenously and does not interact with food. However, patients with electrolyte imbalances may require dietary adjustments (e.g., low potassium or low sodium diet) as directed by their physician.
No direct food interactions; however, patients should avoid high-potassium foods (e.g., bananas, oranges, tomatoes) if hyperkalemia is a concern. Monitor dietary sodium and fluid intake as per clinical status.
No fetal risks have been associated with Plasma-Lyte 148 in Water. It is an isotonic crystalloid solution containing electrolytes and water, lacking known teratogenic properties. No trimester-specific risks reported.
ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid administration may cause maternal fluid and electrolyte disturbances that can indirectly affect the fetus. Use with caution in the setting of impaired uteroplacental perfusion.
Plasma-Lyte 148 components are endogenous and normally present in breast milk. No specific M/P ratio available; expected to be safe during lactation with usual clinical monitoring.
ISOLYTE E is compatible with breastfeeding. Electrolytes are normally present in breast milk; exogenous administration does not significantly alter infant exposure. M/P ratio not applicable as drug is not a xenobiotic.
Pregnancy may increase total body water and electrolyte requirements; dose adjustments are generally not required but individualize based on maternal status and volume deficits.
No dose adjustment is required for pregnancy. However, pregnant patients may have increased plasma volume and altered renal function; infusion rates should be individualized based on clinical status and serum electrolyte monitoring. Rapid correction of electrolyte imbalances should be avoided to prevent fetal osmotic shifts.
PLASMA-LYTE 148 is a balanced crystalloid solution with physiologic concentrations of electrolytes and p H 7.4. It is preferred over normal saline in patients with hyperchloremic metabolic acidosis or renal impairment. Avoid in patients with severe hyperkalemia, hypercalcemia, or metabolic alkalosis. Do not administer simultaneously with blood products through the same IV line due to risk of hemolysis from calcium content.
ISOLYTE E is a balanced electrolyte solution with 5% dextrose, used for maintenance fluid therapy. Monitor serum potassium closely in renal impairment; contains 20 m Eq/L potassium. Caution in patients with hyperkalemia, renal failure, or metabolic alkalosis. Do not administer simultaneously with blood products due to risk of hemolysis. Observe for signs of fluid overload in patients with heart failure.
This solution is given intravenously to replace fluids and electrolytes.,Report any signs of allergic reaction like rash, itching, or difficulty breathing immediately.,Tell your healthcare provider if you have kidney disease, heart failure, or are on a low-sodium diet.,Inform your doctor if you are pregnant, breastfeeding, or taking any medications.,The infusion site should be monitored for redness, swelling, or pain.
This solution is used to replace fluids and electrolytes and provide calories. Tell your doctor if you have kidney problems, heart disease, or are on a low-potassium diet. Report any swelling, shortness of breath, or irregular heartbeat. Do not take over-the-counter potassium supplements without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER vs ISOLYTE E IN PLASTIC CONTAINER, answered by our medical review team.
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Plasma-Lyte 148 is an isotonic crystalloid solution that provides electrolyte replacement and volume expansion. It mimics plasma electrolyte composition, with acetate and gluconate as bicarbonate precursors that are metabolized to bicarbonate in the liver and kidneys, helping to maintain acid-base balance.. ISOLYTE E IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER and ISOLYTE E IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Intravenous Electrolyte Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER is: Intravenous infusion; dose determined by electrolyte and fluid requirements. Typical adult rate: 25-100 m L/hour.. The standard adult dose of ISOLYTE E IN PLASTIC CONTAINER is: Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER and ISOLYTE E IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER is classified as Category C. No fetal risks have been associated with Plasma-Lyte 148 in Water. It is an isotonic crystalloid solution containing electrolytes and water, lacking known teratogenic properties. N. ISOLYTE E IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid ad. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.